|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Carlson — Professor of Medicine, Division of Oncology and Stanford Medical Informatics, Stanford University Medical Center, Stanford, California. Advisory Committee: Genomic Health Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Pfizer Inc; Paid Research: AstraZeneca Pharmaceuticals LP, Genentech BioOncology. Dr Geyer — Director of Medical Affairs, National Surgical Adjuvant Breast and Bowel Project; Vice-Chair, Department of Human Oncology, Allegheny General Hospital, Pittsburgh, Pennsylvania. No financial interests or affiliations to disclose. Dr Gralow — Associate Professor, Medical Oncology, University of Washington and Fred Hutchinson Cancer Research Center; Director, Breast Medical Oncology, Seattle Cancer Care Alliance/University of Washington, Seattle, Washington. Consulting Agreements: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi-Aventis. Dr Hudis — Chief, Breast Cancer Medicine Service, Solid Tumor Division, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York. Advisory Committee: Amgen Inc, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Consulting Agreements: Bristol-Myers Squibb Company, Genentech BioOncology, Wyeth; Paid Research: AstraZeneca Pharmaceuticals LP, Onyx Pharmaceuticals Inc, Roche Laboratories Inc; Stock Ownership: Genomic Health Inc. Dr Mackey — Medical Oncologist, Cross Cancer Institute; Professor, Medical and Experimental Oncology, University of Alberta; Chair of Research, Northern Alberta Breast Cancer Program; Executive Director, Cancer International Research Group, Edmonton, Canada. Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Roche Laboratories Inc, Sanofi-Aventis. Dr Muss — Professor of Medicine, University of Vermont and Vermont Cancer Center, Hematology Oncology Unit, Burlington, Vermont. Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Pfizer Inc, Roche Laboratories Inc. Dr Paik — Director, Division of Pathology, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, Pennsylvania. Advisory Committee: Genentech BioOncology, GlaxoSmithKline. Dr Perez — Professor of Medicine; Director, Cancer Clinical Study Unit; Director, Breast Cancer Program, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida. Paid Research: Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation. Dr Robert — Co-Chair, Breast Cancer Committee, US Oncology Research Network; Chairman, Cancer Committee, Cancer Center, Inova Fairfax Hospital, Fairfax, Virginia. Advisory Committee: Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Consulting Agreements: Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation; Speakers Bureau: Novartis Pharmaceuticals Corporation. Prof Smith — Professor of Cancer Medicine, Department of Medicine, Breast Unit, The Royal Marsden Hospital, London and Surrey, United Kingdom. Advisory Committee: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi-Aventis; Lecturing: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, GlaxoSmithKline; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Wolff — Associate Professor of Oncology, Breast Cancer Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Paid Research: Roche Laboratories Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
 |
 |
EDITOR
Neil Love, MD
TOPICS
Treatment of Early Breast Cancer
- Select publications
Treatment of Metastatic Breast Cancer
- Select publications
Breast Cancer Update - Think Tank:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
